Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Drug Profile

Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Alternative Names: AAV-ZFP-VEGF; Ad-ZFP-VEGF; AdV-ZFP-VEGF; ZFP TF ATV; ZFP TF therapeutics - Sangamo

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo BioSciences; Sangamo Therapeutics
  • Class Transcription factors; Zinc finger DNA binding proteins
  • Mechanism of Action Genetic transcription modulators; Glial cell line-derived neurotrophic factor agonists; Nav1.8 voltage-gated sodium channel inhibitors; Neuron stimulants; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Age-related macular degeneration; Alzheimer's disease; Cancer; Neuropathic pain; Parkinson's disease

Highest Development Phases

  • Preclinical Alzheimer's disease
  • No development reported Neuropathic pain; Parkinson's disease
  • Discontinued Age-related macular degeneration; Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)
  • 15 May 2017 Minor update in pharmacodynamics data from preclinical studies in Alzheimer's disease released by Sangamo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top